Emil D Kakkis

President & CEO

Emil D Kakkis (President & CEO) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Ultragenyx Pharmaceutical Inc. (RARE). The largest single filing was $1.2M of RARE (54,404 sh × $22.80, as filed), executed Mar 2.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 1 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$1.2M

shares × price, as filed

Last traded

Mar 2

Filed Mar 3

Median ADV $57.1M across their filed names

Open performance→

Volume by month

Buys $0 Sells $6.3M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names

RARE

Ultragenyx Pharmaceutical Inc. RARE · 0 buys · 4 sells 4 filings

Recent filings

RARESALE Ultragenyx Pharmaceutical Inc. View filing → $1.2M
54,404 sh × $22.80
Exec Mar 2
Filed Mar 3 · 5:30 PM ET RARESALE Ultragenyx Pharmaceutical Inc. View filing → $4.2M
98,434 sh across 2 lots
Exec Feb 28 2025
Filed Mar 4 2025 · 5:30 PM ET RARESALE Ultragenyx Pharmaceutical Inc. View filing → $495K
11,727 sh × $42.23
Exec Dec 30 2024
Filed Dec 31 2024 · 5:30 PM ET RARESALE Ultragenyx Pharmaceutical Inc. View filing → $414K
8,273 sh × $50.00
Exec Dec 10 2024
Filed Dec 11 2024 · 5:30 PM ET